Pharmaceuticals
Noted National TCM Master Inaugurates New Infinitus Research and Technology Laboratory
GUANGZHOU, China, Oct. 27, 2023 /PRNewswire/ – The unveiling ceremony for the joint laboratory, a collaboration between Infinitus and theShandong University of Traditional Chinese Medicine dedicated toXuezhuo-turbid blood research, took place at Infinitus Plaza. The event drew attention from over...
2023-10-27 08:00
2019
Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
* Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services forHope Medicine's first-in-class monoclonal antibody drug, HMI-115. * The first-in-class mAb will benefit endometriosis and androgenetic alopecia patients. SHANGHAI, Oct. 26, 20...
2023-10-26 22:49
1606
Clarity and PSI kick off SAR-bisPSMA Phase III
SYDNEY, Oct. 26, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, and PSI CRO AG ("PSI"), a global contract rese...
2023-10-26 21:00
1540
YS Biopharma Announces Receipt of Nasdaq Notice
GAITHERSBURG, Md., Oct. 26, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2023-10-26 20:30
3513
HanAll Biopharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
* Sales recorded KRW 33 billion in Q3 2023, an 11 percent increase from the same period in 2022, due to the sustained growth of major products. * 'HL161ANS', HanAll's second anti-FcRn antibody, demonstrated best-in-class potential through the initial outcome of Phase 1 study. * 'HL192', a Nu...
2023-10-26 19:00
1770
Fapon, LASCCO, Abionic Formed Strategic Collaboration for PSP Sepsis Diagnosis in China
LAUSANNE, Switzerland, Oct. 26, 2023 /PRNewswire/ -- Fapon, a leading life sciences company, entered into a strategic cooperation agreement with two Swiss biotech companies LASCCO SA and Abionic SA, that granted Fapon an exclusive license to utilize the pancreatic stone protein (PSP) biomarker fo...
2023-10-26 18:33
2456
Biosyngen's BST02, the World's First TIL Therapy for Liver Cancer, is Granted an IND Approval by FDA
SINGAPORE, Oct. 26, 2023 /PRNewswire/ -- On October 26, 2023, Biosyngen's TIL therapy BST02 for liver cancer was granted an approval for clinical trial by the US FDA. BST02, a breakthrough product in the field of cell and gene therapy, represents the world's first TIL therapy designed for the tre...
2023-10-26 18:18
2682
World Psoriasis Day 2023: Access for All
STOCKHOLM, Oct. 26, 2023 /PRNewswire/ -- Every year on World Psoriasis Day, October 29th, the international psoriatic disease community unites to raise awareness and fight for progress. The theme of 2023, "Access for All," underscores the vital need for Universal Health Coverage (UHC) to ensure t...
2023-10-26 16:00
2121
Prof. Yongmei Yin at 2023 ESMO: SKB264 (MK-2870), an innovativeTROP2-ADC originating from Chinese biotech, achieves remarkable success in overcoming the therapeutic impasse in HR+/HER2- metastatic breast cancer
CHENGDU, China, Oct. 26, 2023 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) convened its annual meeting inMadrid, Spain, from October 20th to 24th, 2023. As the preeminent academic gathering in the field ofoncology, it brought together global experts in oncology to share the la...
2023-10-26 12:58
2169
The International Diabetic Lower Extremity Symposium of the International Society of Regenerative Medicine and Wound Repair Held
PHUKET, Thailand, Oct. 26, 2023 /PRNewswire/ -- During the period from October 25 to 27, 2023, the International Diabetic Lower Extremity Symposium of the International Society of Regenerative Medicine and Wound Repair is held in Thailand. Over 200 experts and scholars from more than 20 countries ...
2023-10-26 10:29
1837
Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
* The independent data monitoring committee (IDMC) recommended the continuation of the BBT-877 Phase 2a trial based on the initial clinical data from the first 20 participants dosed with theinvestigational product * No safety concerns were raised based on the evaluation of the data presented ...
2023-10-26 07:00
1704
Neuragenex Brings Innovative Fibromyalgia Treatment to Patients Across the US
GULBERT, Ariz., Oct. 25, 2023 /PRNewswire/ -- Neuragenex, the national healthcare provider focused on non-pharmaceutical pain treatment, announced its continued expansion to bring relief to fibromyalgia patients across the country. With clinics now operating in Georgia, Texas, Illinois, Tenness...
2023-10-25 23:23
1406
Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer
JINAN, China, Oct. 25, 2023 /PRNewswire/ -- On October 22, Qilu Pharmaceutical unveiled the latest findings from a multicenter, single-arm Phase II clinical trial at the European Society for Medical Oncology (ESMO) Annual Congress 2023. This trial studied the use of QL1706 (iparomlimab and tuvonr...
2023-10-25 22:33
2131
Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer
JINAN, China, Oct. 25, 2023 /PRNewswire/ -- On October 22, Qilu Pharmaceutical unveiled the latest findings from a multicenter, single-arm Phase II clinical trial at the European Society for Medical Oncology (ESMO) Annual Congress 2023. This trial studied the use of QL1706 (iparomlimab and tuvonr...
2023-10-25 22:15
2003
First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe
SHANGHAI, Oct. 25, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient inEurope has been dosed in the international multi-centre phase 3 clinical trial (NCT05353257) of the company's self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination ...
2023-10-25 21:15
2040
Good Safety Profile and Antitumor Activity: Oral Presentation of Mabwell's 9MW2821 at 2023 ESMO
Shanghai, Oct. 25, 2023 /PRNewswire/ -- ESMO Congress 2023 was held in Madrid, Spain from October 20-24, the preliminary results of the Phase I/II study of 9MW2821 (Nectin-4 targeting ADC) in patients with advanced solid tumors were reported by Dr.Jian Zhang of Fudan University Shanghai Cancer Ce...
2023-10-25 17:46
1735
AMS BioteQ Makes Debut at Medical Japan 2023: Bringing Innovative Healthcare into New Horizons
TAIPEI, Oct. 25, 2023 /PRNewswire/ -- Medical Japan Tokyo was held grandly from October 11 to 13, gathering medical professionals, manufacturers, medical institutions, and research units from around the world. AMS BioteQ Co., Ltd. made its first appearance in the exhibition and became one of the ...
2023-10-25 13:06
1840
Snapdragon Chemistry, a Cambrex Company, Recognized with CPhI Pharma Award for API Development
EAST RUTHERFORD, N.J, Oct. 25, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry has been selected as the winner of the API Development Award, presented at the CPhI Pharma Awards inBarcelona, Spain....
2023-10-25 04:18
2069
Cyrus K. Mirsaidi Named Global CEO to Bridgewest Perth Pharma
--Industry veteran to lead growth for company's CDMO and pharmaceutical supply divisions, NovaCina and LumaCina-- MIAMI and PERTH, Australia, Oct. 25, 2023 /PRNewswire/ -- Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, announced today thatCyrus K. Mirsaidi is ...
2023-10-24 23:17
1598
Phase Ib/II Results of Akeso's PD-1/CTLA-4 Bispecific Antibody for First-Line Treatment of Advanced Hepatocellular Carcinoma Published at 2023 ESMO
HONG KONG, Oct. 24, 2023 /PRNewswire/ -- Akeso announced poster presentation at the 2023 European Society for Medical Oncology (ESMO) Congress from its cadonilimab ( PD-1/CTLA-4 bispecific antibody) combined with lenvatinib for first-line treatment of Advanced Hepatocellular Carcinoma (HCC). The ...
2023-10-24 20:00
1340
Week's Top Stories
Most Reposted
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 313 media titles]
2025-01-22 15:38
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 309 media titles]
2025-01-21 16:00
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
[Picked up by 306 media titles]
2025-01-20 14:27
Blackpanda Recognized with Frost & Sullivan's Asia Pacific Company of the Year Award for Incident Response Excellence
[Picked up by 300 media titles]
2025-01-23 09:00
Infobip Research Unveils Opportunities for Brands to Engage Customers with Rich Communication Services (RCS) across APAC
[Picked up by 291 media titles]
2025-01-20 21:09
Most Read
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
2025-01-21 16:00
7062
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
2025-01-20 14:27
4924
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
2025-01-22 15:38
4899